For decades, we have leveraged our world-class expertise in medicinal chemistry and biology to discover, develop and deliver medicines that offer patients new treatment options.
Hematology
Hematology is central to the identity of Incyte. We are a leader in the discovery and development of therapies for patients with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). Building on this legacy, we are developing mutation-specific targeted therapies across the full MPN spectrum that have the potential to transform treatment for patients.
Oncology
Despite progress, cancer continues to be a leading cause of death worldwide, impacting millions of people. Given the significant unmet medical need, we are advancing research in areas where we believe we can have the greatest impact.
Our focus is on novel biologic targets and pathways in high incidence cancers, and we are exploring both single agents and combinations of targeted and immuno-therapies from both within and beyond our portfolio.
Resources
FOR HEALTHCARE PROFESSIONALS
The Cholangiocarcinoma Europe website helps European healthcare professionals learn more about cholangiocarcinoma (CCA). CCAs are diverse biliary epithelial tumors involving the intrahepatic, perihilar and distal parts of the biliary tree. Each anatomical subtype has distinct epidemiology, molecular characteristics, prognosis and strategy for clinical management.
Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please contact us via email at eumedinfo@incyte.com or phone +800 000 27423 (available 24/7). You can also contact our secretariat via 020-2619300.
You can report adverse reactions to Stichting Lareb (www.lareb.nl for reporting form). Or directly to Incyte Biosciences Medical Information by phone +800 000 27423 (available 24 hours a day) or globalmedinfo@incyte.com or eumedinfo@incyte.com.